Cargando…

Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study

ROS proto‐oncogene 1, receptor tyrosine kinase (ROS1) rearrangements are a crucial therapeutic target in non‐small cell lung cancer (NSCLC). However, there is limited comprehensive analysis of the molecular patterns of ROS1 fusions. This study aimed to address this gap by analysing 135 ROS1 fusions...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Shengyu, Zhang, Fayan, Xu, Mengxiang, Zhang, Lei, Liu, Zhengchuang, Yang, Qiong, Wang, Chunyang, Wang, Baoming, Ma, Tonghui, Feng, Jiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552890/ https://www.ncbi.nlm.nih.gov/pubmed/37584407 http://dx.doi.org/10.1002/1878-0261.13509

Ejemplares similares

Case report: A novel reciprocal ROS1-CD74 fusion in a NSCLC patient partially benefited from sequential tyrosine kinase inhibitors treatment
por: Zhang, Xugang, et al.
Publicado: (2022)

Genomic and Transcriptional Profiling of Chinese Melanoma Patients Enhanced Potentially Druggable Targets: A Multicenter Study
por: Li, Yue, et al.
Publicado: (2022)

A Novel Intergenic Gene Between SLC8A1 and PKDCC-ALK Fusion Responds to ALK TKI WX-0593 in Lung Adenocarcinoma: A Case Report
por: Du, Jia, et al.
Publicado: (2022)

Cucurbitacin E inhibits cellular proliferation and enhances the chemo-response in gastric cancer by suppressing AKt activation
por: Si, Wenzhang, et al.
Publicado: (2019)

Molecular characterization of genomic breakpoints of ALK rearrangements in non‐small cell lung cancer
por: Wang, Zizong, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
por: Drilon, Alexander, et al.
Publicado: (2022)

A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement
por: Zhang, Limin, et al.
Publicado: (2016)

Prevalence of ROS1 fusion in Chinese patients with non‐small cell lung cancer
por: Zhang, Qing, et al.
Publicado: (2018)

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
por: Suda, Kenichi, et al.
Publicado: (2020)

Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study
por: Xia, Hui, et al.
Publicado: (2023)

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
por: Hochmair, Maximilian J., et al.
Publicado: (2020)

The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients
por: Liu, Shaokun, et al.
Publicado: (2020)

Identification of RET fusions in a Chinese multicancer retrospective analysis by next‐generation sequencing
por: Shi, Minke, et al.
Publicado: (2021)

ROS-mediated hypomethylation of PRDX5 promotes STAT3 binding and activates the Nrf2 signaling pathway in NSCLC
por: Cao, Xiang, et al.
Publicado: (2021)

OPRM1-ROS1 Fusion Detected by Next-Generation Sequencing with Circulating DNA in a Patient with EGFR Mutated Advanced NSCLC: A Case Report
por: Zhang, Sicai, et al.
Publicado: (2022)

Knockdown of ANXA1 suppresses the biological behavior of human NSCLC cells in vitro
por: FANG, YING, et al.
Publicado: (2016)

EF24 exerts cytotoxicity against NSCLC via inducing ROS accumulation
por: Chang, Minghui, et al.
Publicado: (2021)

Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies
por: Chen, Shuchen, et al.
Publicado: (2022)

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
por: Ruzzi, Francesca, et al.
Publicado: (2022)

The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients
por: Wu, Guowu, et al.
Publicado: (2022)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
por: Hofman, Véronique, et al.
Publicado: (2022)

WIF-1 gene inhibition and Wnt signal transduction pathway activation in NSCLC tumorigenesis
por: Tang, Qiong, et al.
Publicado: (2017)

Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late‐onset cancers
por: Hao, Shaoyu, et al.
Publicado: (2023)

Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
por: Tyler, Logan C., et al.
Publicado: (2022)

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
por: Brazel, Danielle, et al.
Publicado: (2023)

Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations
por: Huang, Richard S.P., et al.
Publicado: (2020)

Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain
por: Rojo, Federico, et al.
Publicado: (2022)

Detection of ROS1 gene fusions using next-generation sequencing for patients with malignancy in China
por: Li, Ning, et al.
Publicado: (2022)

A Screening Method for the ALK Fusion Gene in NSCLC
por: Murakami, Yoshiko, et al.
Publicado: (2012)

Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways
por: Zhu, Zhongling, et al.
Publicado: (2021)

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
por: Chen, An-guo, et al.
Publicado: (2022)

LncRNA LINC00511 plays an oncogenic role in lung adenocarcinoma by regulating PKM2 expression via sponging miR‐625‐5p
por: Xue, Jinghui, et al.
Publicado: (2020)

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
por: Facchinetti, Francesco, et al.
Publicado: (2019)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

Notch3 regulates ferroptosis via ROS‐induced lipid peroxidation in NSCLC cells
por: Li, Zhikang, et al.
Publicado: (2022)

Associations of Chinese visceral adiposity index and new-onset stroke in middle-aged and older Chinese adults: an observational study
por: Zhang, Hongyu, et al.
Publicado: (2023)

Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib
por: He, Yueming, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ni3fkj4au8ki5922r65u3h658g